TET2 and B-cell chronic lymphocytic leukemia: Nevertheless, disruption of TET2 enhances the therapeutic efficacy of CD19‐targeted T cells, leading to deep molecular remission in a 78‐year‐old patient with chronic lymphocytic leukaemia.107 Thus, the development of refined drugs that reverse normal epigenetic signatures is greatly attractive in the field of cancer research, because such drugs have substantial clinical applications as effective therapies in combination treatments.